Frontier Pharma: Obesity - Identifying and Commercializing First-in-Class Innovation

ResearchMoz added Latest Research Report titled " Frontier Pharma: Obesity - Identifying and Commercializing First-in-Class Innovation " to it's Large Report database.

Obesity is a major growing health concern around the world. In most markets, a person is considered obese if their Body Mass Index (BMI) exceeds 30 kilograms per square meter (kg/m2), calculated by dividing body mass in kilograms by height in meters squared. With the global prevalence continuing to rise, the disease has placed significant burden on healthcare expenditure, as it is also a major risk factor for cardiovascular diseases, diabetes and cancer.

Anti-obesity pharmacotherapy can be used as an adjunct lifestyle modification to improve weight loss in order to significantly reduce obesity-associated health risks in obese patients. However, the use of currently available anti-obesity drugs is largely limited by poor long-term safety and a modest weight loss effect. Despite substantial clinical and regulatory challenges, the early-stage obesity pipeline remains robust, containing a high level of first-in-class innovation that has the potential to be translated into effective and safe weight loss treatments.

Download free Sample PDF report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=471700

Scope

• Historically, the obesity market has suffered from long-term safety concerns and modest efficacy with current treatments, both of which contribute to the low prescription rate and limited widespread use.
• What are the main safety concerns that lead to significant challenges in gaining drug approval in obesity?
• Why is sustainable weight loss difficult to achieve, and what is the implication for future drug development?
• Analysis reveals a high level of innovation and diversity in the pipeline, with 75 first-in-class programs identified to act on 60 unique molecular targets.
• What is the dominant target family across these first-in-class pipeline products?
• How well do they align with the underlying signaling pathways governing the central and peripheral regulation of food intake, and energy expenditure?

Read All Pharmaceutical Market Research Reports @ http://www.researchmoz.us/pharmaceutical-market-reports-38.html

Table of Contents

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3

2 Executive Summary 4
2.1 High Unmet Need Remains in the Obesity Market 4
2.2 Highly Innovative and Diverse Pipeline 4
2.3 Deals Landscape Presents Substantial Investment Opportunities 4

3 The Case for Innovation 5
3.1 Growing Opportunities for Biologic Products 6
3.2 Diversification of Molecular Targets 6
3.3 Innovative First-in-Class Product Developments Remain Attractive 6
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation 7
3.5 Sustained Innovation 7
3.6 GBI Research Report Guidance 8

4 Clinical and Commercial Landscape 9
4.1 Disease Overview 9
4.2 Disease Etiology 9
4.2.1 Genetics 9
4.3 Disease Pathophysiology 10
4.3.1 Central Regulation of Energy Homeostasis 10
4.3.2 Endocrine Regulation in Energy Balance 11
4.3.3 Adipose Tissue and Regulation of Energy Expenditure 11
4.3.4 Dysregulation of Adipokines and Contribution to Obesity and Related Metabolic Disorders 12

About ResearchMoz

ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket
Albany NY - 12207
United States
Tel: +1-518-621-2074
Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG